Sensitizing lung cancer to immunotherapy with a RAS(ON) inhibitor doublet
Abstract
First-generation RAS inhibitory drugs have failed to live up to expectations in the clinic, but a preclinical study of a combination of two ON-state RAS inhibitors, one mutant-selective and one targeting all RAS forms, shows greatly reduced development of drug resistance. Most strikingly, this RAS inhibitor doublet combines very effectively with immune checkpoint blockade, leading to complete immune elimination of even highly refractory cancers with immune-cold tumor microenvironments, generating hope for real progress in tackling RAS-mutant tumors in the clinic. See related article by Wei et al., p. 1152.
Journal details
Journal
Cancer Discovery
Volume
16
Issue number
6
Pages
1044-1046
Available online
Publication date
Full text links
Publisher website (DOI)
10.1158/2159-8290.CD-26-0609
Europe PubMed Central
42220008
Pubmed
42220008
Keywords
Related topics
Type of publication
